Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Depreciation and Depletion (2016 - 2017)

Corvus Pharmaceuticals' Depreciation and Depletion history spans 3 years, with the latest figure at $211000.0 for Q3 2017.

  • Quarterly Depreciation and Depletion rose 32.7% to $211000.0 in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $808000.0 through Sep 2017, up 73.39% year-over-year, with the annual reading at $594000.0 for FY2016, 301.35% up from the prior year.
  • Depreciation and Depletion came in at $211000.0 for Q3 2017, up from $208000.0 in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $211000.0 in Q3 2017 to a low of $1000.0 in Q1 2015.
  • The 3-year median for Depreciation and Depletion is $144000.0 (2016), against an average of $124090.9.
  • Year-over-year, Depreciation and Depletion skyrocketed 10500.0% in 2016 and then soared 32.7% in 2017.
  • Corvus Pharmaceuticals' Depreciation and Depletion stood at $57000.0 in 2015, then surged by 224.56% to $185000.0 in 2016, then rose by 14.05% to $211000.0 in 2017.
  • Per Business Quant, the three most recent readings for CRVS's Depreciation and Depletion are $211000.0 (Q3 2017), $208000.0 (Q2 2017), and $204000.0 (Q1 2017).